

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6958558

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NEWGEN THERAPEUTICS, INC.	05/19/2021
RECEIVING PARTY DATA	
Name:	RAKOVINA THERAPEUTICS INC.
Street Address:	2201-8 SMITHE MEWS
City:	VANCOUVER, BRITISH COLUMBIA
State/Country:	CANADA
Postal Code:	V6B 0A5
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16666307
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	4152686431
Email:	mleung@mofo.com
Correspondent Name:	STEPHANIE CHOING
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	425 MARKET STREET
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94105
ATTORNEY DOCKET NUMBER:	22738-20001.03
NAME OF SUBMITTER:	STEPHANIE CHOING
SIGNATURE:	/Stephanie Choing/
DATE SIGNED:	10/07/2021
Total Attachments: 3	
source=22738-2000103_Newgen_to_Rakovina#page1.tif	
source=22738-2000103_Newgen_to_Rakovina#page2.tif	
source=22738-2000103_Newgen_to_Rakovina#page3.tif	

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: NEWGEN THERAPEUTICS, INC.
Address: 3475 Edison Way, Suite R, Menlo Park, California 94025
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as “Assignor”), which has acquired its ownership, by assignment, in the patent applications identified in Appendix A, attached herewith.

This Assignment is to:

Assignee: RAKOVINA THERAPEUTICS INC.
Address: 2201-8 Smithe Mews, Vancouver, British Columbia, Canada V6B 0A5
A juristic entity duly organized under and pursuant to the laws of: Canada

(referred to in this Assignment as “Assignee”), which desires to acquire the entire right, title and interest in, to and under said patent applications in Appendix A and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in confirmation of any obligation to do so in accordance with the terms in the Purchase and Patent Assignment Agreement dated March 19, 2021 between Assignor and Assignee.

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor’s entire right, title and interest in and to the above-mentioned inventions, applications for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

3. Assignor hereby grants Assignee’s attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.


4. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

5. Assignee hereby accepts the assignment of the patent applications identified in Appendix A.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).


ASSIGNOR:

Date: 19-May/2021

Signature: /  /
Name: Jeffrey Bacha
Title: Chairman and CEO
Company: NEWGEN THERAPEUTICS, INC.

ASSIGNEE:

Date: 19-May/2021

Signature: /  /
Name: Jeffrey Bacha
Title: Executive Chairman
Company: RAKOVINA THERAPEUTICS INC.

Appendix A

Official No.	Case Status	Country
16/666,307	Filed	United States of America
2,875,025	Filed	Canada
2714703	EP Granted	European Patent Office
5960253	Granted/Registered	Japan
21161257.7	Filed	European Patent Office